Skip to content
Next results · Q4 2026Projected

Mar 10, before the open

Wed, Mar 10, 2027in 113 days

Projected from its last 8 releases. The company has not named the day yet.

Quarter
Q4 2026 · Ends about Dec 31, 2026
10-K window
Mar 5 – 12

Read against Q4 2025

The same quarter a year earlier, the figures the next ones will be compared with. Thaler holds no estimates.

Revenue
$9.25M
Revenue, change from a year earlier: Q3 2026 +924.7%, Q2 2026 +112.7%, Q1 2026 −45.1%, Q4 2025 +223.8%
Net income
-$21.66M
Net income, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q4 2025 n/m
EPS
—
EPS, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q3 2025 n/m

Results day

Typical moveA typical move of 7.6% either way

Up after 8 of 12, down after 4.

The stock’s move from the last close before each release to the first close after it, over the last 12 releases. Largest: +13.9% after Q2 2026.

Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

When it reports

Usual day
Varies
Session
before the open
After quarter end
36 to 65 days
10-Q filed
36 to 40 days
over its last 8
10-K filed
67 to 70 days
over its last 6

Based on 6 prior 10-K filings.

Foghorn Therapeutics Inc. · CIK 1822462 · Engraved from SEC EDGAR